The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
The UK’s swift authorisation of Biontech and Pfizer’s Covid-19 shot has attracted both praise and concern.
Despite the lack of an overall survival benefit the Seal study gives Karyopharm enough to file for Xpovio’s first solid tumour use.
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
Bristol Myers Squibb and Merck & Co hail front-line successes, but histology and biomarker status will remain live issues for doctors.